SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use [package insert]. North Chesterfield, VA: Indivior PLC; 2025. Jones AK, Ngaimisi E, Gopalakrishnan M, Young MA, Laffont CM.

RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder ...

Sublocade offers important benefits not currently provided by the sublingual form of buprenorphine. Medication is steadily released into the blood stream, which helps patients to be compliant with ...

(RTTNews) - Indivior PLC (INDV) announced the FDA has approved label changes for SUBLOCADE including a rapid initiation protocol and alternative injection sites. Healthcare providers can now ...

SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use [package insert]. North Chesterfield, VA: Indivior PLC; 2025. Jones AK, Ngaimisi E, Gopalakrishnan M, Young MA, Laffont CM.

Alternative Injection Sites: SUBLOCADE can now be administered subcutaneously in the abdomen, thigh, buttock, or back of the upper arm, offering patients and healthcare providers increased ...